Industry Concerned About Excipient Registration and Data Protection Under FDASIA
This article was originally published in The Gold Sheet
FDA faces a heavy workload in implementing the supply chain provisions of FDASIA, yet developing a unique facility identifier (UFI) for foreign and domestic establishments will be a priority, as many aspects of the law hinge on having this identifier, said an agency official. In the meantime, there are questions concerning the workability of FDASIA’s excipient registration provision and whether confidential information will be protected when FDA exchanges information with foreign governments during inspections.
You may also be interested in...
The user fee legislation Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains. The bill directs FDA to inspect based on risk rather than time or location, and to rely on trusted foreign inspectorates, while adding new user fees for generic drugs that will boost funding for further expansion of the agency’s inspectorate.
Hospitals will have a large role in success of these treatments, with a high level of teamwork and coordination required between the technical operations team and the commercial teams working in tight time-frames.
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.